Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Clinical evidence

EMERGE

44 evidence topics · 16 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using MG-ADL as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm in the November 2026 corporate deck
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

EMERGE began on 2026-06-29 and has reported no efficacy or safety results; the company expects top-line results in the second half of 2028, and a company presentation lists updated EMERGE top-line guidance by the end of 2027. Enrollment is limited to approximately 195 adults aged 18 to 80 years who are acetylcholine receptor antibody positive, with an MG-ADL score of 6 or more and a QMG score of 10 or more, so participants with anti-MuSK, anti-LRP4, or seronegative generalized myasthenia gravis are not represented. The randomized, placebo-controlled period lasts 17 weeks, and longer-term data will come from an optional 104-week extended treatment period that includes an open-label extension.